Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

On May 18, 2022 Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, reported that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually (Press release, AEterna Zentaris, MAY 18, 2022, View Source;id=231826&p=2229442&I=1206939-c7Z3G6f3m8 [SID1234614816]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.

A video webcast of the presentation will be accessible for viewing on-demand beginning on Tuesday, May 24, 2022, at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investors section of the Company’s website (zentaris.com). The webcast replay will be archived for 90 days following the event.

Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

On May 18, 2022 Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, reported that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at H.C. Wainwright’s upcoming Annual Global Investment Conference (Press release, Candel Therapeutics, MAY 18, 2022, View Source [SID1234614815]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Format: Pre-recorded corporate presentation
Date/Time: May 24, 2022, on-demand viewing starts at 7:00 am ET

To access the webcast recording of the company presentation, please visit the Candel Therapeutics website at View Source

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

On May 18, 2022 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, reported that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic, will present at the H.C. Wainwright Global Investment Conference being held in Miami, FL and virtually on Wednesday, May 25, 2022 at 4:00 PM ET (Press release, Xenetic Biosciences, MAY 18, 2022, https://ir.xeneticbio.com/news/detail/121/xenetic-biosciences-inc-to-present-at-the-h-c-wainwright-global-investment-conference [SID1234614809]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Xenetic Biosciences, Inc., Wednesday, May 18, 2022, Press release picture
In addition to the presentation, members of the management team will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.

A live video webcast of the presentation will be available on the Events page in the Investors section of the Company’s website (xeneticbio.com) and archived for 90 days following the event.

UroGen Pharma to Present at Upcoming Investor Conferences

On May 18, 2022 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, reported that it will present at the following healthcare conferences (Press release, UroGen Pharma, MAY 18, 2022, View Source [SID1234614808]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. Global Investment Conference

Wednesday, May 25 at 11:00 a.m. ET
Jefferies Healthcare Conference

Thursday, June 9 at 1:00 p.m. ET
Webcasts of both the H.C. Wainwright & Co. and Jefferies presentations will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.

Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

On May 18, 2022 Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, reported that management is scheduled to present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 9:30 AM EDT (Press release, Pieris Pharmaceuticals, MAY 18, 2022, View Source [SID1234614805]). A webcast of the company’s presentation will be available at this link.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!